Does dose escalation via intraoperative radiation improve outcomes for GBM?
In the EXTEND trial, did circulating tumor DNA predict disease control outcomes after ablative radiation for oligometastatic cancer?
In the TREASURE trial, did consolidative thoracic radiation improve survival in patients who received induction chemoimmunotherapy for ES-SCLC?
Answers
No, in INTRAGO II, there was no difference in OS with or without intraoperative RT, and most recurrences were still within 1 cm of the resection cavity.
Yes. Detectable baseline ctDNA predicted inferior disease control while ctDNA clearance at 3 months was associated with improved survival.
No. In fact, the trial was stopped early due to a higher rate of severe adverse events and fatal events in the TRT arm. | QuadShot News
In the EXTEND trial, did circulating tumor DNA predict disease control outcomes after ablative radiation for oligometastatic cancer?
In the TREASURE trial, did consolidative thoracic radiation improve survival in patients who received induction chemoimmunotherapy for ES-SCLC?
Answers
No, in INTRAGO II, there was no difference in OS with or without intraoperative RT, and most recurrences were still within 1 cm of the resection cavity.
Yes. Detectable baseline ctDNA predicted inferior disease control while ctDNA clearance at 3 months was associated with improved survival.
No. In fact, the trial was stopped early due to a higher rate of severe adverse events and fatal events in the TRT arm. | QuadShot News